Triad Life Sciences Closes A$25M Funding
- Triad Life Sciences, a Memphis, Tenn.-based biotech company, raised AUS$25m funding round
- The convertible note placement was led by Cannacord Genuity
- The company intends to use the funds for its US sales force expansion plans, R&D activities, and general working capital needs
- Triad now plans to move forward with a listing on the Australian Securities Exchange (ASX) in the coming months
- Led by CEO Russ Olsen, TriadLife Sciences is a biotech company focused on developing and commercializing biomaterials for treating complex surgical and chronic wounds
- Triad recently received FDA clearance to market InnovaMatrix™, a next generation extracellular matrix (ECM) wound care device
